Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

The 12-11 vote supporting new indication for reduced incidence of cardiovascular death provides cover for FDA if it decides more data are needed before granting first CV benefit claim to a diabetes drug.


Related Content

US FDA May Change Requirements For CV Outcomes Trials For Type 2 Diabetes Drugs
Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Jardiance's Label Expansion Will Change Diabetes Management
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts